Current Practices in the Management of Cancer Therapy-Induced Emesis
This information was originally presented on September 21, 2013, at the NCCN 8th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Summarize the risk factors for development of cancer therapy-induced emesis and the current standards of care in antiemesis management
Kim Noonan, MS, RN, ANP, AOCN
Dana-Farber/Brigham and Women's Cancer Center
- 0.50 Participation
- 0.38 Nurse
- 0.50 Pharmacist
- 0.50 Physician